Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Collaboration
PhoreMost Enters Multi-Project Drug Target Discovery Collaboration with Roche
Details : Novel targets identified will be further validated and characterised by Roche’s R&D organisation, and any SITESEEKER-based probes would become the starting point for drug discovery efforts across a set of disease pathways in immunology and haematology.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Vipergen
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the terms of the agreement Vipergen will apply its leading technologies for DNA-encoded library synthesis and screening including DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost protein targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 14, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Vipergen
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : LentiVector based gene therapy
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Oxford Biomedica
Deal Size : Undisclosed
Deal Type : Collaboration
PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies
Details : PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 09, 2020
Lead Product(s) : LentiVector based gene therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Oxford Biomedica
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?